-
-
-
-
-
-
-
PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF
-
-
-
-
-
-
-
PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondar
-
-
-
-
-
-
-
PureTech Health plc – Half-Year Report
-
-
-
-
-
-
-
PureTech Health's (PRTC) Akili Announces Phase 3 Study of Digital Treatment in Children with ADHD Begun by Shionogi in Japan
-
-
-
-
-
-
-
PureTech Founded Entity Akili Appoints Game Industry Veteran Behind Bejeweled, Plants vs. Zombies as Chief Product Officer
-
-
-
-
-
-
64,524 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

